These therapies include Norditropin®, which is frequently prescribed for a variety of growth-related conditions. In the medical field, it’s used for:
- Low or non-existent growth hormone levels in children
- Children with the Noonan or Turner syndromes, which cause them to be short in stature,
- Small-for-gestational-age (SGA) infants who have not caught up in growth from age 2 to 4 years old are considered short (in stature).
- Short-statured children who have no underlying medical condition, hormonal imbalance, or malnutrition (Idiopathic Short Stature)
- Prader-Willi syndrome is a condition in which children are unable to grow (PWS). Adults with insufficient levels of growth hormone production.
Copay assistance program of Norditropin
It is a prescription drug, called Norditropin®. In order to help those who are eligible, Novo Nordisk offers financial assistance.
There are times when an insurance policy does not kick in immediately. If the initial claim is rejected and the medical counselor is aiding with the appeal process, coverage may be delayed as a result of normal processing time.
Your Case Manager may discuss the copay assistance program with you if you anticipate a delay in receiving insurance coverage. This program provides qualifying patients with a limited amount of free Norditropin®. Even if the claim is denied, experts will not bill you for this medication.
To get a source of Norditropin® for 1 year, patients must meet program eligibility criteria & financial need requirements and must re-qualify thirty (30) days before the PAP expiration date.
Norditropin® prescriptions for an FDA-approved evidence and commercial insurance coverage may qualify patients for a limited source of free good or service.
A patient’s participation in any government-funded medical and prescription benefit programs, such as TRICARE or VA or DOD-funded medical or prescription benefits, is ineligible for participation.
This excludes patients participating in a managed Medicaid program or having Medicaid as secondary insurance.
